Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.

Sinagra, E., Tomasello, G., Raimondo, D., Rossi, F., Facella, T., Perricone, G., et al. (2013). MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES: CLINICAL EVIDENCES AND POTENTIAL INSIGHTS FOR THE CLINICIANS. INTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION, 1(3).

MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES: CLINICAL EVIDENCES AND POTENTIAL INSIGHTS FOR THE CLINICIANS

TOMASELLO, Giovanni;PALUMBO, Vincenzo Davide;SPINELLI, Gabriele;DAMIANO, Giuseppe;COTTONE, Mario
2013

Abstract

Mesenchimal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies MSCs can be safely transplanted in autologous and allogenic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that the properties may also be exploited of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. aim of this review is to analyze the pathophysiological insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.
Settore MED/18 - Chirurgia Generale
Settore MED/04 - Patologia Generale
Settore MED/08 - Anatomia Patologica
http://scidoc.org/articles%20pdf/ijst/IJST-01-301.pdf
Sinagra, E., Tomasello, G., Raimondo, D., Rossi, F., Facella, T., Perricone, G., et al. (2013). MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES: CLINICAL EVIDENCES AND POTENTIAL INSIGHTS FOR THE CLINICIANS. INTERNATIONAL JOURNAL OF STEM CELL RESEARCH AND TRANSPLANTATION, 1(3).
File in questo prodotto:
File Dimensione Formato  
MESENCHIMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASES. IJST 2013.pdf

accesso aperto

Dimensione 301.73 kB
Formato Adobe PDF
301.73 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/84523
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact